SCYNEXIS, Inc. (SCYX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SCYX POWR Grades
- Growth is the dimension where SCYX ranks best; there it ranks ahead of 88.33% of US stocks.
- The strongest trend for SCYX is in Quality, which has been heading down over the past 178 days.
- SCYX's current lowest rank is in the Quality metric (where it is better than 1.57% of US stocks).
SCYX Stock Summary
- SCYX's price/sales ratio is 19.21; that's higher than the P/S ratio of 93.97% of US stocks.
- Revenue growth over the past 12 months for SCYNEXIS INC comes in at -66.86%, a number that bests only 2.75% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SCYX comes in at -103.45% -- higher than that of only 5.71% of stocks in our set.
- Stocks that are quantitatively similar to SCYX, based on their financial statements, market capitalization, and price volatility, are HTGM, WPRT, IRBT, SOFO, and BKYI.
- SCYX's SEC filings can be seen here. And to visit SCYNEXIS INC's official web site, go to www.scynexis.com.
SCYX Valuation Summary
- SCYX's price/sales ratio is 19.2; this is 860% higher than that of the median Healthcare stock.
- Over the past 104 months, SCYX's price/sales ratio has gone up 14.7.
Below are key valuation metrics over time for SCYX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SCYX | 2022-11-25 | 19.2 | 4.6 | -1.0 | -0.8 |
| SCYX | 2022-11-23 | 19.2 | 4.6 | -1.0 | -0.8 |
| SCYX | 2022-11-22 | 19.3 | 4.7 | -1.0 | -0.8 |
| SCYX | 2022-11-21 | 19.5 | 4.7 | -1.0 | -0.8 |
| SCYX | 2022-11-18 | 17.8 | 4.3 | -1.0 | -0.7 |
| SCYX | 2022-11-17 | 16.2 | 3.9 | -0.9 | -0.6 |
SCYX Growth Metrics
- The year over year net income to common stockholders growth rate now stands at 36.36%.
- The 5 year price growth rate now stands at -72.25%.
- The 4 year price growth rate now stands at -72.25%.
The table below shows SCYX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 4.164 | -82.597 | -77.623 |
| 2022-06-30 | 3.123 | -76.675 | -48.644 |
| 2022-03-31 | 1.8 | -69.789 | -33.641 |
| 2021-12-31 | 13.163 | -54.56 | -32.866 |
| 2021-09-30 | 12.566 | -45.612 | -46.334 |
| 2021-06-30 | 12.05 | -38.895 | -44.82 |
SCYX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SCYX has a Quality Grade of C, ranking ahead of 29.3% of graded US stocks.
- SCYX's asset turnover comes in at 0.134 -- ranking 232nd of 682 Pharmaceutical Products stocks.
- ACER, QURE, and MNOV are the stocks whose asset turnover ratios are most correlated with SCYX.
The table below shows SCYX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.134 | 1 | -3.908 |
| 2021-03-31 | 0.169 | 1 | -5.208 |
| 2020-12-31 | 0.000 | NA | -3.192 |
| 2020-09-30 | 0.000 | NA | -1.322 |
| 2020-06-30 | 0.000 | NA | -1.486 |
| 2020-03-31 | 0.001 | 1 | -1.353 |
SCYX Price Target
For more insight on analysts targets of SCYX, see our SCYX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $24.36 | Average Broker Recommendation | 1.36 (Strong Buy) |
SCYX Stock Price Chart Interactive Chart >
SCYX Price/Volume Stats
| Current price | $2.45 | 52-week high | $7.87 |
| Prev. close | $2.45 | 52-week low | $1.70 |
| Day low | $2.42 | Volume | 124,400 |
| Day high | $2.50 | Avg. volume | 189,444 |
| 50-day MA | $2.40 | Dividend yield | N/A |
| 200-day MA | $2.74 | Market Cap | 80.01M |
SCYNEXIS, Inc. (SCYX) Company Bio
SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.
Latest SCYX News From Around the Web
Below are the latest news stories about SCYNEXIS INC that investors may wish to consider to help them evaluate SCYX as an investment opportunity.
SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal ThreatsBARDA is seeking to support the development of broad-spectrum, oral/IV antifungal drug candidates with novel mechanisms of action that target Candida species, including Candida auris, and Aspergillus species.Ibrexafungerp, a first-in-class, broad-spectrum oral/IV antifungal meets all the priorities outlined by BARDA in its new Broad Agency Announcement (BAA) released this week, and has shown activity against multiple drug-resistant pathogens, including C. auris, C. albicans, C. glabrata, C. para |
SCYNEXIS Third Quarter 2022 Earnings: Misses ExpectationsSCYNEXIS ( NASDAQ:SCYX ) Third Quarter 2022 Results Key Financial Results Net loss: US$29.6m (loss widened by US$29.0m... |
Ladenburg Thalmann & Co. Reaffirms Their Buy Rating on SCYNEXIS (SCYX)E ratio of -1.13. |
Analysts’ Top Healthcare Picks: Larimar Therapeutics (LRMR), SCYNEXIS (SCYX)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMR – Research Report) and SCYNEXIS (SCYX – Research Report) with bullish sentiments. Larimar Therapeutics (LRMR) JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Larimar Therapeutics today and set a price target of $16.00. The company's shares closed last Thursday at $3.07, close to its 52-week low of $1.53. According to TipRanks.com, Wolleben is ranked 0 out of 5 stars with an average return of -38.9% and a 14.0% success rate. |
Scynexis (SCYX) Reports Q3 Loss, Misses Revenue EstimatesScynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
SCYX Price Returns
| 1-mo | 1.24% |
| 3-mo | -3.16% |
| 6-mo | 15.02% |
| 1-year | -66.89% |
| 3-year | -77.31% |
| 5-year | -87.69% |
| YTD | -59.84% |
| 2021 | -20.26% |
| 2020 | -15.93% |
| 2019 | 89.58% |
| 2018 | -79.31% |
| 2017 | -27.27% |
Continue Researching SCYX
Want to do more research on Scynexis Inc's stock and its price? Try the links below:Scynexis Inc (SCYX) Stock Price | Nasdaq
Scynexis Inc (SCYX) Stock Quote, History and News - Yahoo Finance
Scynexis Inc (SCYX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...